Side-by-side comparison of AI visibility scores, market position, and capabilities
Paradromics is developing the Connexus fully implantable BCI for speech restoration in paralyzed patients; received FDA IDE approval and completed first human implant at University of Michigan in May 2026;
Paradromics is a neurotechnology company based in Austin, Texas, focused on developing brain-computer interface (BCI) technology specifically for restoring communication and independence to patients with severe paralysis caused by ALS, stroke, and spinal cord injury. The company's lead product, the Connexus BCI, is a fully implantable neural interface system designed to record high-resolution neural signals from the motor cortex and decode them into speech output — enabling patients who have lost the ability to speak or move to communicate through their thoughts.
Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.